Japan MHLW approves Novocure's Optune Lua for advanced NSCLC

NovoCure Ltd

Japan MHLW approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors in advanced/recurrent NSCLC after platinum-based chemo.
Approval based on Phase 3 LUNAR trial: median OS 13.2 vs 9.9 months (3.3-month improvement, p=0.04).
In PD-1/PD-L1 subgroup, median OS 19.0 vs 10.8 months (8.2-month improvement, p=0.02).
Optune Lua is a wearable TTFields device; device-related AEs were mostly grade 1-2 skin reactions.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.